TG Therapeutics announces launch of phase 1/2 study of TGR-1202 and Carfilzomib
TG Therapeutics announced the launch of a Phase 1/2 study to evaluate the safety and efficacy of TGR-1202, the Company's oral PI3K delta inhibitor in combination with carfilzomib, the FDA-approved proteasome inhibitor, in patients with relapsed or refractory lymphoma. October 20, 2016